Norris Perne & French’s BioMarin Pharmaceuticals BMRN Stock Holding History

Norris Perne & French’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,000	Closed	-$247K	–	151
2020 Q2	$247K	Buy	+2,000	New	+$199K	0.03%	122
2016 Q1	–	Sell	-2,000	Closed	-$210K	–	145
2015 Q4	$210K	Hold	2,000	–	–	0.04%	145
2015 Q3	$211K	Hold	2,000	–	–	0.05%	139
2015 Q2	$274K	Hold	2,000	–	–	0.05%	126
2015 Q1	$249K	Buy	+2,000	New	+$212K	0.05%	139

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Norris Perne & French's BMRN Position: Q3 2020 in Review

Norris Perne & French sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 2,000 shares — an estimated $247K sold.

Norris Perne & French first reported a position in BMRN in Q1 2015 and held it in 5 quarters. The position peaked at $274K in Q2 2015. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Norris Perne & French reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Norris Perne & French sold 2,000 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $247K.
Norris Perne & French first reported a position in BioMarin Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Norris Perne & French's BioMarin Pharmaceuticals position peaked at $274K in Q2 2015.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Norris Perne & French's 13F filing for Q3 2020, filed 26 Oct 2020.